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abSTracT
Polycystic kidney disease (PKD) is the commonest life-
threatening genetic disease, affecting 12.5 million people 
worldwide.   It is found in all races and occurs equally in men 
and women.  PKD is characterized by the growth of numerous 
fluid-filled cysts that can profoundly enlarge while replacing 
much of the normal renal structure, resulting in reduced 
kidney function and subsequently to renal failure.1
TWo Major inheriTeD forMS of pKD:
The adult type of PKD has an autosomal dominant type of 
inheritance (aka ADPKD) and accounts for approximately 90% of 
all PKD cases.  Symptoms usually develop between the ages of 30 
and 40, but they can begin earlier, even in childhood.  
The less common childhood form of PKD is characterised 
by an autosomal recessive pattern of inheritance (aka ARPKD).  







ADPKD is a multi-systemic and progressive disorder 
characterized by cyst formation and enlargement in the kidney and 
other organs.  Up to 50% of patients with ADPKD require renal 
replacement therapy by 60 years of age.
A number of conditions are well-recognised as being 
associated with ADPKD:
•	 cerebral berry aneurysms
•	 found in 6% of patients with ADPKD without a family 
history of aneurysms
•	 found in up to 16% of patients with ADPKD with a 
family history
•	 intracranial dolichoectasia: 2-3% of ADPKD cases
•	 hypertension: up to 80% of ADPKD cases
•	 diverticular disease
•	 valvular heart disease eg. bicuspid aortic valve or mitral valve 
prolapse (up to 25% of ADPKD cases)
•	 aortic dissection
•	 cysts in other organs including:  liver, spleen, pancreas, ovaries, 
seminal vesicles and prostate.
SyMpToMS
Clinical presentation is variable and includes: 
•	 dull flank pain of variable severity and time course 
•	 abdominal / flank masses
•	 haematuria or recurrent urinary tract infections
•	 hypertension which usually develops at the same time as renal 
failure
•	 renal functional impairment to renal failure.
Other symptomatology can arise when above-mentioned 
complications arise.3
STephanie aTTarD
pKD iS characTerizeD by The GroWTh 
of nuMerouS fLuiD-fiLLeD cySTS 
ThaT can profounDLy enLarGe WhiLe repLacinG 
Much of The norMaL renaL STrucTure
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DiaGnoSiS
1. Imaging studies most commonly with ultrasonography; CT or 
MRI scans are also widely used.  
2. Genetic testing is used to detect mutations in one of two 
genes:  PKD1 or PKD2.4
PKD1 is located on chromosome 16p and is responsible for 
85% of cases. It is associated with earlier presentation and is more 
likely to progress to ESRD.
PKD2 is located on chromosome 4q, is responsible for 15% of 
cases of ADPKD and is typically less severe.
A third rare type of ADPKD (termed ADPKD 3) has been 
described, however the gene has yet to be identified.5
oTher inVeSTiGaTionS incLuDe:
•	 Standardized blood pressure screening as per American Heart 
Association recommendations.
•	 Measurement of blood lipid concentrations because 
hyperlipidemia is a correctable risk factor for progressive 
renal disease.
•	 Urine studies to detect the presence of microalbuminuria/
proteinuria, which in the presence of severe renal cystic 
disease, indicates an increased likelihood of disease 
progression and mandates strict control of the blood pressure.
•	 Echocardiography to diagnose valvular heart disease.
•	 Echocardiography or cardiac MRI to screen patients at high 
risk because of a family history of thoracic aortic dissections.
•	 Head MRI or CT angiography to screen patients for intra-
cerebral aneurysms.4
DiaGnoSTic criTeria
For patients from families with ADPKD of unknown 
genotype, the following is sufficient for making the diagnosis: 
1. in individuals between 15 and 39 years of age, the presence of 
≥3 unilateral/bilateral kidney cysts; 
2. in individuals between 40 and 59 years of age, ≥2 cysts in each 
kidney; 
3. in individuals ≥60 years of age, ≥ 4 cysts in each kidney;
4. at least 2 cysts in each kidney by age 30 in a patient with 
a family history of ADPKD  can confirm the diagnosis. If 
there is any question about the diagnosis, a family history of 
ADPKD and cysts found in other organs make the diagnosis 
more likely.6
ManaGeMenT
Current therapy is directed towards reducing morbidity and 
mortality from the renal and extra-renal complications.
Hypertension The antihypertensive agent(s) of choice have 
not been clearly established. Because of the role of the renin-
angiotensin system in the pathogenesis of hypertension in 
ADPKD, ACE inhibitors and angiotensin II receptor antagonists 
may be superior to other agents in individuals with preserved renal 
function.7  
Flank pain After excluding causes of flank pain that may 
require intervention, such as infection, stone, or tumor, an initial 
conservative approach to pain management is best:
•	 Nonopioid agents are preferred and care should be taken 
to avoid long-term administration of nephrotoxic agents 
such as analgesic and nonsteroidal anti-inflammatory drug 
combination.
•	 Tricyclic antidepressants.
•	 Narcotic analgesics should be reserved for the management of 
acute episodes.
•	 Splanchnic nerve blockade with local anesthetics/steroids.
When conservative measures fail, therapy can be directed 
toward cyst decompression with cyst aspiration and sclerosis.  
In individuals with many cysts contributing to pain, surgical 
interventions can be considered including:
•	 Laparoscopic or surgical cyst fenestration through lumbotomy 
or flank incision, 
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•	 Renal denervation
•	 In those who have reached ESRD - nephrectomy.8
Cyst hemorrhage and gross hematuria - usually self-limiting 
and respond well to conservative management with bed rest, 
analgesics, and adequate hydration to prevent development of 
obstructing clots.
Rarely, episodes of bleeding are severe with extensive 
subcapsular or retroperitoneal hematoma, significant drop 
in hematocrit, and hemodynamic instability. In such cases, 
individuals require hospitalization, transfusion, and investigation 
by CT or angiography.  In cases of unusually severe or persistent 
hemorrhage, segmental arterial embolization can be successful.  If 
not, surgery may be required to control bleeding.8
Nephrolithiasis - The treatment of nephrolithiasis in 
individuals with ADPKD is the same as that for individuals 
without ADPKD:
•	 High fluid intake and potassium citrate are the treatment of 
choice in uric acid lithiasis, hypocitraturic calcium oxalate 
nephrolithiasis, and distal acidification defects.
•	 Urine alkalinization (to maintain a pH of 6-6.5), and 
administration of allopurinol. 
•	 Extracorporeal shock-wave lithotripsy and percutaneous 
nephrostolithotomy.4
Cyst infection - often difficult to treat and has a high treatment 
failure rate despite prolonged therapy with an antibiotic to which 
the organism is susceptible. Treatment failure results from the 
inability of certain antibiotics to penetrate the cyst epithelium 
successfully and achieve therapeutic concentrations within 
the cyst. Therapeutic agents of choice include trimethoprim-
sulfamethoxazole and fluoroquinolones. Clindamycin, 
vancomycin, and metronidazole are also able to penetrate cysts 
well. Chloramphenicol has shown therapeutic efficacy in otherwise 
refractory disease.9
Malignancy - The diagnosis of renal cell carcinoma in a PKD 
patient requires a high index of suspicion.  MRI with gadolinium 
enhancement is particularly helpful to detect atypical solid or 
cystic masses, tumor thrombi, and regional lymphadenopathy.
The diagnosis of transitional cell carcinoma in a polycystic 
kidney is equally challenging and usually requires retrograde 
pyelography or ureteroscopy.
End-stage renal disease -  Therapeutic interventions aimed 
at slowing the progression of ESRD in ADPKD include control 
of hypertension and hyperlipidemia, dietary protein restriction, 
control of acidosis, and prevention of hyperphosphatemia.
Actuarial data indicate that individuals with ADPKD do 
better on dialysis than individuals with ESRD from other causes.  
Females appear to do better than males.  The reason for this 
improved outcome is unclear but may relate to better-maintained 
haemoglobin levels through higher endogenous erythropoietin 
production.10
SurVeiLLance
Intracranial aneurysms - Widespread screening is neither 
cost-effective nor indicated because most intracranial aneurysms 
found by screening asymptomatic individuals are small, have a low 
risk of rupture, and require no treatment.
Indications for screening in 20- to 50-year-olds with a good 
life expectancy include a family history of intracranial aneurysms 
or subarachnoid hemorrhage, previous rupture of an aneurysm, 
preparation for elective surgery with potential hemodynamic 
instability, high-risk occupations such as airplane pilots, and 
significant anxiety on the part of the individual despite adequate 
risk information.
Magnetic resonance angiography is the diagnostic imaging 
modality of choice for presymptomatic screening.  Schrier et al 
recommended rescreening after an interval of ten years because 
one of 76 individuals with an initial negative study had a new 
intracranial aneurysm after a mean follow-up of 9.8 years.11,12
Aortic dissection - Until more information becomes 
available, it is reasonable to screen first-degree adult relatives 
of individuals with thoracic aortic dissection using either 
echocardiography or MRI.  If aortic root dilatation is found, 
yearly follow-up and strict blood pressure control with beta 
blockers should be recommended.
aGenTS/circuMSTanceS To aVoiD
•	 Long-term administration of nephrotoxic agents such as 
analgesic and NSAID combinations.
•	 Caffeine because it interferes with the breakdown of cAMP 
and hence may promote renal cyst growth.




Several promising candidate drugs have been suggested 
including:
•	 Tolvaptan, a vasopressin type 2 receptor antagonist - a 5-year 
multicentre trial which was concluded in 2012 showed that 
Tolvaptan, as compared with placebo, slowed the increase 
in total kidney volume and the decline in kidney function 
over a 3-year period in patients with ADPKD. However, it 
was associated with a higher discontinuation rate, owing to 
adverse events.13
•	 Octreotide, a somatostatin analogue, has been shown to 
inhibit kidney growth in a small double-blind, placebo-
controlled study done in 2010.14 A phase 3 clinical trial 
investigating the efficacy of Octreotide in slowing or even 
halting the kidney enlargement and renal function decline 
in ADPKD patients with moderate/severe renal failure, is 
underway (ALADIN 2 study).
•	 Calcineurin inhibitors - initial studies had shown that 
treating adults with ADPKD and early chronic kidney 
disease with sirolimus did not halt polycystic kidney 
growth.15 On the other hand, when compared with placebo 
over a 2-year study period, everolimus slowed the increase 
in total kidney volume of patients with ADPKD but did not 
slow the progression of renal impairment.16 Further clinical 
trials on the efficacy and long-term safety of sirolimus and 
everolimus are underway. 
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